| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:seeAlso
| |
| Description
| - Objective. Lipoprotein-associated phospholipase A2 (Lp-PLA 2) is extensively expressed by advanced atherosclerotic lesions and may play a role in plaque instability. We selected a group of elderly subjects that underwent transcatheter aortic valve implantation (TAVI) or balloon angioplasty (BA) and separated them into two groups, diabetic and nondiabetic, to compare the level of Lp-PLA2 mass between them. Methods. 44 patients aged 79.6 +- 5.6 years with symptomatic severe aortic valve stenosis underwent TAVI (n = 35) or BA (n = 9). 21 subjects had confirmed type 2 diabetes mellitus. Lp-PLA2 mass was measured using an enzyme-linked immunosorbent assay kit (USCN Life Science, China) before and 3 days after the procedure. Results. Lp-PLA2 mass was significantly elevated in this population (1296 +- 358 ng/mL before TAVI; 1413 +- 268 ng/mL before BA) and further increased after TAVI (1604 +- 437 ng/mL, P < 0. 01) or BA (1808 +- 303 ng/mL, P < 0. 01). Lp-PLA2 mass was significantly increased on the diabetic group before these interventions. Conclusion. Lp-PLA2 may be a novel biomarker for the presence of rupture-prone atherosclerotic lesions in elderly patients. Levels of Lp-PLA 2 in diabetic patients may accompany the higher amount of small dense LDL particles seen in these subjects. (C) 2014 J. Fortunato et al.
- Objective. Lipoprotein-associated phospholipase A2 (Lp-PLA 2) is extensively expressed by advanced atherosclerotic lesions and may play a role in plaque instability. We selected a group of elderly subjects that underwent transcatheter aortic valve implantation (TAVI) or balloon angioplasty (BA) and separated them into two groups, diabetic and nondiabetic, to compare the level of Lp-PLA2 mass between them. Methods. 44 patients aged 79.6 +- 5.6 years with symptomatic severe aortic valve stenosis underwent TAVI (n = 35) or BA (n = 9). 21 subjects had confirmed type 2 diabetes mellitus. Lp-PLA2 mass was measured using an enzyme-linked immunosorbent assay kit (USCN Life Science, China) before and 3 days after the procedure. Results. Lp-PLA2 mass was significantly elevated in this population (1296 +- 358 ng/mL before TAVI; 1413 +- 268 ng/mL before BA) and further increased after TAVI (1604 +- 437 ng/mL, P < 0. 01) or BA (1808 +- 303 ng/mL, P < 0. 01). Lp-PLA2 mass was significantly increased on the diabetic group before these interventions. Conclusion. Lp-PLA2 may be a novel biomarker for the presence of rupture-prone atherosclerotic lesions in elderly patients. Levels of Lp-PLA 2 in diabetic patients may accompany the higher amount of small dense LDL particles seen in these subjects. (C) 2014 J. Fortunato et al. (en)
|
| Title
| - Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus
- Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus (en)
|
| skos:prefLabel
| - Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus
- Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus (en)
|
| skos:notation
| - RIV/00216208:11150/14:10283845!RIV15-MSM-11150___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| - Jurašková, Božena
- Brtko, Miroslav
- Bis, Josef
- Vojáček, Jan
- Sobotka, Luboš
- Andrýs, Ctirad
- Polanský, Pavel
- Šťásek, Josef
- Bláha, Vladimír
- Fortunato, Joao
|
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11150/14:10283845
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - target; biology; enzymes; lysophosphatidylcholine; risk; atherosclerosis; coronary plaque; metabolic syndrome; cardiovascular disease; acticating-factor-acetylhydrolase (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - EG - Egyptská arabská republika
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Journal of Diabetes Research
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Andrýs, Ctirad
- Brtko, Miroslav
- Jurašková, Božena
- Sobotka, Luboš
- Vojáček, Jan
- Bis, Josef
- Polanský, Pavel
- Šťásek, Josef
- Bláha, Vladimír
- Fortunato, Joao
|
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| http://bibframe.org/vocab/doi
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)